Samuel E. DePrimo
About
Samuel E. DePrimo is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Samuel E. DePrimo has authored 40 papers receiving a total of 5.3k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Biology, 20 papers in Oncology and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Samuel E. DePrimo's work include Renal cell carcinoma treatment (6 papers), Psoriasis: Treatment and Pathogenesis (5 papers) and Cancer-related Molecular Pathways (5 papers). Samuel E. DePrimo is often cited by papers focused on Renal cell carcinoma treatment (6 papers), Psoriasis: Treatment and Pathogenesis (5 papers) and Cancer-related Molecular Pathways (5 papers). Samuel E. DePrimo collaborates with scholars based in United States, France and Italy. Samuel E. DePrimo's co-authors include Carlo L. Bello, Charles M. Baum, M. Dror Michaelson, Brian I. Rini, Robert J. Motzer, Sindy T. Kim, Daniel J. George, Gary R. Hudes, Robert A. Figlin and Éric Raymond and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.
In The Last Decade
Samuel E. DePrimo
40 papers receiving 5.2k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Samuel E. DePrimo United States | 28 | 2.7k | 2.5k | 2.2k | 1.3k | 496 | 40 | 5.3k | ||
| Robert Justice United States | 40 | 2.8k 1.0× | 1.7k 0.7× | 2.5k 1.2× | 871 0.7× | 558 1.1× | 61 | 6.4k | ||
| Ferry A.L.M. Eskens Netherlands | 43 | 2.6k 0.9× | 1.5k 0.6× | 2.9k 1.3× | 1.2k 0.9× | 601 1.2× | 161 | 6.4k | ||
| Neeltje Steeghs Netherlands | 37 | 1.7k 0.6× | 1.9k 0.8× | 2.8k 1.3× | 857 0.7× | 523 1.1× | 242 | 5.4k | ||
| Markus Borner Switzerland | 43 | 1.8k 0.7× | 1.8k 0.7× | 3.0k 1.4× | 847 0.6× | 541 1.1× | 126 | 5.6k | ||
| Petri Bono Finland | 44 | 2.7k 1.0× | 2.4k 1.0× | 3.9k 1.8× | 1.6k 1.2× | 479 1.0× | 156 | 7.5k | ||
| Miao‐Zhen Qiu China | 38 | 1.6k 0.6× | 1.6k 0.6× | 2.5k 1.2× | 1.3k 1.0× | 595 1.2× | 165 | 4.9k | ||
| Ferdinando De Vita Italy | 43 | 2.0k 0.7× | 2.2k 0.9× | 3.4k 1.6× | 1.0k 0.8× | 540 1.1× | 207 | 6.0k | ||
| Michele Orditura Italy | 44 | 1.9k 0.7× | 2.1k 0.9× | 3.4k 1.6× | 1.0k 0.8× | 502 1.0× | 181 | 6.1k | ||
| E. Gabriela Chiorean United States | 42 | 2.1k 0.8× | 1.5k 0.6× | 4.7k 2.1× | 1.7k 1.3× | 441 0.9× | 209 | 7.1k | ||
| Carlo L. Bello United States | 27 | 3.1k 1.1× | 4.1k 1.7× | 3.1k 1.4× | 1.5k 1.1× | 549 1.1× | 54 | 7.5k |
Countries citing papers authored by Samuel E. DePrimo
Since
Specialization
Citations
This map shows the geographic impact of Samuel E. DePrimo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Samuel E. DePrimo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Samuel E. DePrimo more than expected).
Fields of papers citing papers by Samuel E. DePrimo
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Samuel E. DePrimo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Samuel E. DePrimo. The network helps show where Samuel E. DePrimo may publish in the future.
Co-authorship network of co-authors of Samuel E. DePrimo
This figure shows the co-authorship network connecting the top 25 collaborators of Samuel E. DePrimo. A scholar is included among the top collaborators of Samuel E. DePrimo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Samuel E. DePrimo. Samuel E. DePrimo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Chen, Yanqing, Samuel E. DePrimo, Ernesto J. Muñoz‐Elías, et al.. (2023). Guselkumab for hidradenitis suppurativa: a phase II, open-label, mode-of-action study. British Journal of Dermatology. 188(5). 601–609.
2.
Boyle, David L., Samuel E. DePrimo, César A. Calderón, et al.. (2019). Toreforant, an orally active histamine H4-receptor antagonist, in patients with active rheumatoid arthritis despite methotrexate: mechanism of action results from a phase 2, multicenter, randomized, double-blind, placebo-controlled synovial biopsy study. Inflammation Research. 68(4). 261–274.
3.
Loesche, Michael A., Kamyar Farahi, Kimberly Capone, et al.. (2018). Longitudinal Study of the Psoriasis-Associated Skin Microbiome during Therapy with Ustekinumab in a Randomized Phase 3b Clinical Trial. Journal of Investigative Dermatology. 138(9). 1973–1981.
4.
DePrimo, Samuel E., et al.. (2018). 451 Association between HLA-Cw6 status and response to guselkumab in patients with moderate to severe plaque psoriasis. Journal of Investigative Dermatology. 138(5). S76–S76.
5.
Zurita, Amado J., Mehrdad Khajavi, L. Tye, et al.. (2015). Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours. British Journal of Cancer. 112(7). 1199–1205.
6.
Harmon, Charles S., Samuel E. DePrimo, Robert A. Figlin, et al.. (2013). Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma. Cancer Chemotherapy and Pharmacology. 73(1). 151–161.
7.
Keyvanjah, Kiana, Samuel E. DePrimo, Charles S. Harmon, et al.. (2012). Soluble KIT correlates with clinical outcome in patients with metastatic breast cancer treated with sunitinib. Journal of Translational Medicine. 10(1). 165–165.
8.
Harmon, Charles S., Samuel E. DePrimo, Éric Raymond, et al.. (2011). Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib. Journal of Translational Medicine. 9(1). 120–120.
9.
DePrimo, Samuel E., Xin Huang, Martin E. Blackstein, et al.. (2009). Circulating Levels of Soluble KIT Serve as a Biomarker for Clinical Outcome in Gastrointestinal Stromal Tumor Patients Receiving Sunitinib following Imatinib Failure. Clinical Cancer Research. 15(18). 5869–5877.
10.
George, Suzanne, Jean‐Yves Blay, Paolo G. Casali, et al.. (2009). Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. European Journal of Cancer. 45(11). 1959–1968.
11.
Rini, Brian I., M. Dror Michaelson, Jonathan E. Rosenberg, et al.. (2008). Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology. 26(22). 3743–3748.
12.
Motzer, Robert J., M. Dror Michaelson, Bruce G. Redman, et al.. (2005). Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology. 24(1). 16–24.
13.
Faivre, Sandrine, Catherine Delbaldo, Karina Vera, et al.. (2005). Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer. Journal of Clinical Oncology. 24(1). 25–35.
14.
DePrimo, Samuel E., Deepak Khatry, William C. Manning, et al.. (2003). Expression profiling of blood samples from an SU5416 Phase III metastatic colorectal cancer clinical trial: a novel strategy for biomarker identification. BMC Cancer. 3(1). 3–3.
15.
Agarwal, Munna L., Chilakamarti V. Ramana, Mark Hamilton, et al.. (2001). Regulation of p53 expression by the RAS-MAP kinase pathway. Oncogene. 20(20). 2527–2536.
16.
DePrimo, Samuel E., Rajesh Shinghal, Genevieve M. Vidanes, & James D. Brooks. (2001). PREVENTION OF PROSTATE CANCER. Hematology/Oncology Clinics of North America. 15(3). 445–457.
17.
DePrimo, Samuel E., et al.. (1998). Use of Human Placental Alkaline Phosphatase Transgenes to Detect Somatic Mutation in Micein Situ. Methods. 16(1). 49–61.
18.
DePrimo, Samuel E., et al.. (1998). In situ detection of frameshift mutation in mouse cells. Mutation research. Fundamental and molecular mechanisms of mutagenesis. 421(2). 163–178.
19.
Cao, Jiawei, Samuel E. DePrimo, & James R. Stringer. (1997). Cell cycle dependence of radiation-induced homologous recombination in cultured monkey cells. Mutation research. Fundamental and molecular mechanisms of mutagenesis. 374(2). 233–243.
20.
DePrimo, Samuel E., Peter J. Stambrook, & James R. Stringer. (1996). Human placental alkaline phosphatase as a histochemical marker of gene expression in transgenic mice. Transgenic Research. 5(6). 459–466.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Robert Justice Breakdown of academic impact, for papers by Ferry A.L.M. Eskens Breakdown of academic impact, for papers by Neeltje Steeghs Breakdown of academic impact, for papers by Markus Borner Breakdown of academic impact, for papers by Petri Bono Breakdown of academic impact, for papers by Miao‐Zhen Qiu Breakdown of academic impact, for papers by Ferdinando De Vita Breakdown of academic impact, for papers by Michele Orditura Breakdown of academic impact, for papers by E. Gabriela Chiorean Breakdown of academic impact, for papers by Carlo L. Bello